Close Menu

NEW YORK (360Dx) – Shares of Laboratory Corporation of America were down 11 percent in morning trading today following the company's announcement that it was lowering its full-year 2018 guidance on the top and bottom lines.

Total revenue growth is expected to be in the range of 9.9 percent to 10.3 percent year over year, down from prior guidance of 10.5 percent to 11 percent growth. Revenue growth for LabCorp Diagnostics is expected to be in the range of 2.1 percent to 2.5 percent, down from prior guidance of 3 percent to 3.5 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.